中国生物制药回应F-star重回私营:属常规性业务调整,国际化战略没有变化

界面
Yesterday

4月7日,中国生物制药向界面新闻回应此前收购的英国双抗公司F-star Therapeutics重回私营一事。中国生物制药表示,本次交易是F-star的早期探索平台回归由目前的管理团队独立运营,属于常规性业务调整,具体交易细节,因为受保密义务约束,现阶段不便对外披露详细信息。另外,中国生物制药的国际化作为公司四大战略之一,没有任何变化。公司海外子公司Invox在2024年作了架构调整,主要聚焦海外...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10